Header Background.jpg
Faknostics Logo.png

INTEGRATING SCIENCE

& THERAPEUTICS

RESEARCH AT FAKNOSTICS LLC IS FOCUSED ON DEVELOPMENT OF BOTH DIAGNOSTICS AND THERAPEUTICS AROUND THE MAJOR CANCER PROTEIN FOCAL ADHESION KINASE (FAK)

FAKnostics LLC is a dynamic diagnostics and pharmaceutical company.

 

We are developing next generation drugs that inhibit tumor growth through targeting important protein-protein interactions on the FAK scaffold.

DISCOVER MORE
Green Arrow V2.png
FakBuildg.jpg
PUBLICATIONS

We have been publishing research on FAK since 1993

See our entire list of academic publications.

mltiBookswider2 (1).png
COLORECTAL CANCER

We recently demonstrated and published that Stage 1 colorectal cancer patients with high FAK have a significantly increased recurrence and lower overall survival prognosis. 

Purple cell.png
Blue Arrow V2.png
PATHOLOGY & PROGNOSTICS
CANCER
HOMECancerProgtext box.png
CANCER

FAK is considered to be an especially promising cancer drug target for solid tumors.

We have developed an effective inhibitor that targets the kinase independent FAT domain of FAK with efficacy at nanomolar dosage.

Twirly things.png
PLASTIC SURGERY

We are currently testing the effectiveness and dosing of our FAK inhibitor for the reduction of skin fibrosis with a view towards plastic surgery applications

Plastic Surgery.png
FIBROSIS

FAK over-expression is associated with fibrosis induced by biochemical stress.

We are developing our proprietary FAK inhibitor to target liver fibrosis induced by NAFLD, alcoholism and infectious diseases.

Green Arrow V2.png
pipetLong thin.png